Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

Muto, A; Yoshihashi, K; Takeda, M; Kitazawa, T; Soeda, T; Igawa, T; Sakamoto, Y; Haraya, K; Kawabe, Y; Shima, M; Yoshioka, A; Hattori, K

Muto, A; Yoshihashi, K; Takeda, M; Kitazawa, T; Soeda, T; Igawa, T; Sakamoto, Y; Haraya, K; Kawabe, Y; Shima, M; Yoshioka, A; Hattori, K.

J Thromb Haemost ; 12(2): 206-13, 2014 Feb.

Article in En | MEDLINE | ID: mdl-24738137

Subject(s)

Antibodies/immunology; Factor IXa/immunology; Factor X/immunology; Hemophilia A/therapy; Hemostasis/immunology; Animals; CHO Cells; Cricetinae; Cricetulus; Cross Reactions; Disease Models, Animal; HEK293 Cells; Humans; Macaca fascicularis; Male

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Factor X / Factor IXa / Hemophilia A / Hemostasis / Antibodies Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Thromb Haemost Year: 2014 Document type: Article

Search on Google

XML

PubMed Links